Reprotech and TMRW Life Sciences have announced a strategic business combination, bringing together Reprotech’s 35+ years of cryostorage leadership and national biorepository network with TMRW’s digital specimen management platform and automated storage technology. The combined company will operate under the Reprotech banner and feature the TMRW, Matcher, and Cryologix brands.
The scale is significant: The combined organization will safeguard more than one million fertility specimens, partner with approximately 75% of U.S. fertility centers, support more than 50% of U.S. patient cycles, and operate eight offsite storage facilities.
TMRW Life Sciences CEO Louis Villalba will lead the combined company as CEO, with Reprotech CEO Brad Senstra serving as COO.
“There is clear industrial logic in bringing Reprotech and TMRW together,” said Luis A. Fernandez, chairman of the Reprotech board. “We are building a company designed to meet the evolving demands of the fertility industry by combining state of the art infrastructure, trusted service, and next-generation technology.”
The combination addresses a structural shift in the fertility industry: The move from fresh to frozen cycles is creating cryostorage volumes far beyond what most clinic infrastructure was designed to handle. As egg freezing grows (more than 40,000 women froze their eggs in 2023 alone) and IVF cycles increasingly rely on frozen embryo transfers, the demand for scalable, digitally managed storage is becoming a critical infrastructure need.
TMRW built the world’s first automated platform for managing and storing frozen sperm, eggs, and embryos – replacing manual systems that carry inherent risk. Reprotech brings the physical infrastructure with five purpose-built biorepositories and established digital witnessing and billing platforms.
The combined entity is positioned as the dominant infrastructure layer for fertility specimen management in the U.S., with plans to expand internationally.
